Document is current

Article History

Received: 7 June 2024

Accepted: 16 August 2024

First Online: 7 September 2024

Declarations

:

: Ethics approval was granted from the Ontario Cancer Research Ethics Board (#4334), and will be obtained in all other jurisdictions that open the trial. Written informed consent will be obtained from all participants. Consent will be obtained at individual participating institutions by study investigators or clinical trials staff members.

: Not applicable.

: David Palma reports research funding from the Ontario Institute for Cancer Research, royalties from UptoDate.com, and has a consultant role with equity with Need Inc, unrelated to the current study. Meredith Giuliani reports participation in advisory boards for AstraZeneca and Bristol Myers Squibb, unrelated to the current study. Stephen Harrow has received honoraria from AstraZeneca, Pfizer, and Takeda Pharamaceuticals, has consulted for AstraZeneca, and has received travel, accommodations and expenses reimbursements from AstraZeneca and Takeda Pharmaceuticals, unrelated to current study. Houda Bahig reports research grants from Varian Medical Systems, research grants and honoraria from AstraZeneca, and honoraria from Sanofi, unrelated to the current study. Robert Olson reports grant funding from Varian Medical Systems, and has a consultant role with equity with Need Inc, unrelated to the current study. Michael Lock reports consulting fees from Bayer and Tersera, and honoraria from Knight Therapeutics, Abbvie and Eisai, unrelated to the current study. Glenn Bauman reports research grants from the Ontario Institute for Cancer Research, participation in advisory boards for Advanced Accelerator Applications, and is the Clinical Lead, CTP for the Ontario Institute for Cancer Research, unrelated to the current study. Benjamin Lok reports research grants from Pfizer, and research grants, honoraria, and non-financial support from AstraZeneca, unrelated to the current study. Rachel Glicksman reports research grants from Astellas and TerSera, and honoraria from Bayer, TerSera, Knight Therapeutics and Tolmar. Christopher Goodman reports participation in advisory boards for AstraZeneca and a consultant role with equity with Need Inc, unrelated to the current study. Lucas Mendez reports research grants from the Terry Fox Research Institute, Academic Medical Organization of Southwestern Ontario (AMOSO) Opportunities, Ride For Dad (London, Ontario), Abbvie CARO Uro-Oncologic Radiation Awards (ACURA), Academic Medical Organization of Southwestern Ontario (AMOSO) Innovation, and Varian Medical Systems, and has received honoraria from Knights Therapeutics, and has participated in a data safety monitoring board for the London Regional Cancer Program, unrelated to the current study. All other authors report no competing interests.